Matthew E. Korenberg - Nov 1, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President & COO
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Matthew E. Korenberg
Stock symbol
LGND
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/3/2022, 09:10 PM
Previous filing
Aug 4, 2022
Next filing
Dec 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +27.7K +47.53% $0.00 86K Nov 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 19,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2 Includes securities that were adjusted pursuant to an anti-dilution provision in connection with the separation of the OmniAb, Inc. from the Issuer on November 1, 2022.

Remarks:

Exhibit 24 - Power of Attorney.